Today the US Supreme Court will hear arguments in Case No. 24-889. Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al. Case No. 24-889. concerns 1. When a generic drug label fully carves out a patented use, are allegations that the generic drugmaker calls its product a 'generic version' and cites public information about the branded drug (e.g., sales) enough to plead induced infringement of the patented use? and 2. Does a complaint state a claim for induced infringement of a patented method if it does not allege any instruction or other statement by the defendant that encourages, or even mentions, the patented use?